References
1. Ho MH, Wong WH, Heine RG, et al.
Early clinical predictors of remission of peanut allergy in children.J Allergy Clin Immunol . 2008;121 (3):731-6.
2. Skolnick HS, Conover-Walker MK,
Koerner CB, et al. The natural history of peanut allergy. J
Allergy Clin Immunol . 2001;107 (2):367-74.
3. Bock SA, Atkins FM. The natural
history of peanut allergy. J Allergy Clin Immunol .
1989;83 :900-4
4. Sampson HA, Mendelson L, Rosen JP.
Fatal and near-fatal anaphylactic reactions to food in children and
adolescents. N Engl J Med . 1992;327 (6):380-4.
5. Baldwin M, Spong A, Doward L, et
al. Patient-reported outcomes, patient-reported information: from
randomized controlled trials to the social web and beyond.Patient . 2011;4 (1):11-7.
6. Haslam A, Herrera-Perez D, Gill J,
et al. Patient Experience Captured by Quality-of-Life Measurement in
Oncology Clinical Trials. JAMA Netw Open .
2020;3 (3):e200363.
7. Chinthrajah RS, Purington N, Andorf
S, et al. Sustained outcomes in oral immunotherapy for peanut allergy
(POISED study): a large, randomised, double-blind, placebo-controlled,
phase 2 study. Lancet . 2019;394 (10207):1437-49.
8. Syed A, Garcia MA, Lyu SC, et al.
Peanut oral immunotherapy results in increased antigen-induced
regulatory T-cell function and hypomethylation of forkhead box protein 3
(FOXP3). J Allergy Clin Immunol . 2014;133 (2):500-10.
9. Chu DK, Wood RA, French S, et al.
Oral immunotherapy for peanut allergy (PACE): a systematic review and
meta-analysis of efficacy and safety. Lancet .
2019;393 (10187):2222-32.
10. Tang ML, Ponsonby AL, Orsini F,
et al. Administration of a probiotic with peanut oral immunotherapy: A
randomized trial. J Allergy Clin Immunol .
2015;135 (3):737-44 e8.
11. Hsiao K-C, Ponsonby A-L, Axelrad
C, et al. Long-term clinical and immunological effects of Probiotic and
Peanut Oral Immunotherapy (PPOIT) post-treatment cessation: Four-year
follow-up of a randomized double-blind placebo-controlled trial.Lancet Child Adolesc Health . 2017;1 (2):97-105.
12. Dunn Galvin A, McMahon S,
Ponsonby AL, et al. The longitudinal impact of probiotic and peanut oral
immunotherapy on health-related quality of life. Allergy .
2018;73 (3):560-8.
13. DunnGalvin A, de BlokFlokstra BM,
Burks AW, et al. Food allergy QoL questionnaire for children aged 0-12
years: content, construct, and cross-cultural validity. Clin Exp
Allergy . 2008;38 (6):977-86.
14. Van der Velde JL, Flokstra-de
Blok BM, Vlieg-Boerstra BJ, et al. Development, validity and reliability
of the food allergy independent measure (FAIM). Allergy .
2010;65 (5):630-5.
15. Echeverría-Zudaire L,
Fernández-Fernández S, Rayo-Fernández A, et al. Primary eosinophilic
gastrointestinal disorders in children who have received food oral
immunotherapy. Allergol Immunopathol . 2016;44 (6):531-6.
16. Lucendo AJ, Arias A, Tenias JM.
Relation between eosinophilic esophagitis and oral immunotherapy for
food allergy: a systematic review with meta-analysis. Ann Allergy,
Asthma Immunol . 2014;113 (6):624-9.
17. Petroni D, Spergel JM.
Eosinophilic esophagitis and symptoms possibly related to eosinophilic
esophagitis in oral immunotherapy. Ann Allergy, Asthma Immunol .
2018;120 (3):237-40.
18. Vickery BP, Scurlock AM, Kulis M,
et al. Sustained unresponsiveness to peanut in subjects who have
completed peanut oral immunotherapy. J Allergy Clin Immunol .
2014;133 (2):468-75.
19. Vickery BP, Vereda A, Casale TB,
et al. AR101 Oral Immunotherapy for Peanut Allergy. N Engl J Med. 2018;379 (21):1991-2001.
20. Virkud YV, Burks AW, Steele PH,
et al. Novel baseline predictors of adverse events during oral
immunotherapy in children with peanut allergy. J Allergy Clin
Immunol . 2017;139 (3):882-8.
21. Miettinen M, Matikainen S,
Vuopio-Varkila J, et al. Lactobacilli and streptococci induce
interleukin-12 (IL-12), IL-18, and gamma interferon production in human
peripheral blood mononuclear cells. Infect Immun .
1998;66 (12):6058-62.
22. Pessi T, Sutas Y, Hurme M, et al.
Interleukin-10 generation in atopic children following oral
Lactobacillus rhamnosus GG. Clin Exp Allergy.2000;30 (12):1804-8.
23. Rautava S, Arvilommi H, Isolauri
E. Specific probiotics in enhancing maturation of IgA responses in
formula-fed infants. Pediatr Res . 2006;60 (2):221-4.
24. Narisety SD, Frischmeyer-Guerrerio PA, Keet CA, et al. A randomized,
double-blind, placebo-controlled pilot study of sublingual versus oral
immunotherapy for the treatment of peanut allergy. J Allergy Clin
Immunol . 2015;135 (5):1275-82.e1-6.
25. Jones SM, Pons L, Roberts JL, et al. Clinical efficacy and immune
regulation with peanut oral immunotherapy. J Allergy Clin
Immunol . 2009;124 (2):292-300, .e1-97.